PERRIGO Co plc
Perrigo Co plc is a consumer self-care company focused on over-the-counter health and wellness products sold through retail and pharmacy channels. Its portfolio spans store-brand and branded products across North America and Europe, including infant formula, upper respiratory, nutrition, women’s health, oral care, skin care, and other everyday self-care categories.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenuePrivate-label OTC health products sold through retail and pharmacy customers.
Consumer health brands sold under Perrigo-owned names in key markets.
Infant formula and related nutrition products sold in North America and other markets.
Products such as emergency contraception and related women’s health items.
Products including skin care, wound care, and topical consumer health items.
Additional OTC and wellness categories such as oral care and upper respiratory.
Customers
Perrigo sells primarily to large retail chains, mass merchants, pharmacies, and other consumer health distributors that stock store-brand and branded OTC products. End demand comes from consumers seeking affordable, accessible self-care products without a prescription, while Perrigo’s customers buy to fill shelf space, support category breadth, and offer value-priced alternatives. The company also serves a small number of large customers, with Walmart representing a significant share of sales in the latest reported year.
They buy store-brand OTC products and branded consumer health items to support shelf assortment and value pricing.
They purchase OTC remedies and wellness products for prescription-adjacent and self-care aisles.
They source branded and private-label products for regional or specialty retail distribution.
They buy Perrigo-branded and store-brand products for everyday self-care needs and affordability.
Strategy
Perrigo’s strategy centers on consumer-led innovation, stronger branded and store-brand demand generation, and a more efficient global supply chain. The company also emphasizes portfolio focus, with capital and management attention directed toward categories and brands that can scale across geographies and channels. Its operating model is built to support value-priced self-care products while expanding adjacent categories and new product launches.
Keeps the portfolio relevant and supports shelf space with retail customers.
Concentrates resources on categories with stronger strategic fit and scale.
A more efficient network supports service levels, cost control, and resilience.
Manufacturing and quality improvements are intended to support this business line.
Geography
Q1/2026Perrigo’s business is concentrated in North America and Europe, with those regions forming the core of its consumer self-care platform. North America is especially important for store-brand leadership and products such as Opill and Mederma, while Europe is anchored by brands including Compeed, ellaOne, Solpadeine, Jungle Formula, and ACO. The company’s manufacturing, sourcing, and regulatory footprint spans multiple countries, so product availability and compliance depend on regional supply chains and local market rules.
Share of the revenue the company reports by geography.
Risks
Perrigo faces the usual consumer health risks of competition, regulation, product quality, and raw-material volatility, but its business is also exposed to retail concentration and supply-chain disruption. Because many products are sold through a small number of large customers and manufactured through a global network, service failures, recalls, or logistics interruptions can quickly affect sales and reputation. The company also carries meaningful goodwill and impairment risk tied to category performance and portfolio changes.
- Goodwill impairmentImpact: HighLikelihood: High
The company has large goodwill balances and uses impairment testing that can produce non-cash charges when expectations change.
Exposure: CSCA and CSCI reporting units
- Customer concentrationImpact: HighLikelihood: Medium
A small number of large retailers account for a meaningful share of sales, so lost shelf space or weaker terms can hurt revenue.
Exposure: Walmart and other top customers
- Supply chain disruptionImpact: HighLikelihood: Medium
Global sourcing and manufacturing create exposure to plant outages, logistics issues, labor shortages, and geopolitical events.
Exposure: Manufacturing and distribution network
- Regulatory and product quality riskImpact: HighLikelihood: Medium
OTC and infant formula products operate in regulated categories where compliance or safety issues can stop shipments or damage trust.
Exposure: Self-care and infant formula portfolios
- Raw material and input cost volatilityImpact: MediumLikelihood: High
Ingredient and packaging costs can move quickly and are difficult to fully pass through in retail channels.
Exposure: OTC formulations and packaging
Accounting
Judgemental itemsImpairment tests depend on fair value, cash-flow, and market assumptions; changes can trigger large charges.
Impact: CSCA and CSCI goodwill balances and earnings
Businesses under strategic review or divestiture are reclassified and measured differently.
Impact: Asset presentation and disposal gains/losses
Consumer health products require estimates for obsolescence, returns, and quality-related provisions.
Impact: Gross margin and working capital
Retail sell-in, rebates, and returns can affect the timing and amount of recognized revenue.
Impact: Quarterly sales comparability
Similar listed companies
Publicly listed companies with a comparable business focus.
Prestige Consumer Healthcare Inc.
PBH · Pharmaceutical Preparations
Kenvue Inc.
KVUE · Perfumes, Cosmetics & Other Toilet Preparations
Caring Brands, Inc.
CABR · Perfumes, Cosmetics & Other Toilet Preparations
Haleon plc
HLN · Perfumes, Cosmetics & Other Toilet Preparations
Haleon plc is a consumer health company focused on everyday self-care and over-the-counter wellness products.
Starco Brands, Inc.
STCB · Services-Advertising Agencies
Opko Health, Inc
OPK · Pharmaceutical Preparations
OPKO Health is a U.S.-based biopharmaceutical and diagnostics company with operations spanning pharmaceutical development, commercial products, laboratory testing, and product licensing.
Last updated: 24/09/2026